ReviewInternational journal of molecular sciences2020
CARs: Beyond T Cells and T Cell-Derived Signaling Domains.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Pathology associated with human CAR T cell administration in NOD.Cg-Veterinary pathology · 2026Article
- Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.Journal of hematology & oncology · 2026Review
- CAR T-cells for the treatment of CNS malignancies.Frontiers in immunology · 2026Review
- Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation.Annals of hematology · 2025Article
- Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers.Cancer immunology, immunotherapy : CII · 2024Article
- Nanobody-based CAR NK cells for possible immunotherapy of MICAPNAS nexus · 2024Article
- Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.Methods in molecular biology (Clifton, N.J.) · 2024Article
- CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy.Cancer cell international · 2023Review
- Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.Frontiers in immunology · 2023Review
- Diverse Neutrophil Functions in Cancer and Promising Neutrophil-Based Cancer Therapies.International journal of molecular sciences · 2022Review
- The CD8α hinge is intrinsically disordered with a dynamic exchange that includes proline cis-trans isomerization.Journal of magnetic resonance (San Diego, Calif. : 1997) · 2022Article
- CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy.Advanced pharmaceutical bulletin · 2022Review
- Advances in NK cell production.Cellular & molecular immunology · 2022Review
- Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges.Cancers · 2022Review
- CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review.Frontiers in oncology · 2022Article
- T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors.International journal of molecular sciences · 2020Review
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.Cancers · 2020Review
- Nucleic Acid-Based Approaches for Tumor Therapy.Cells · 2020Review
- Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
When optimizing chimeric antigen receptor (CAR) therapy in terms of efficacy, safety, and broadening its application to new malignancies, there are two main clusters of topics to be addressed: the CAR design and the choice of transfected cells. The former focuses on the CAR construct itself. The utilized transmembrane and intracellular domains determine the signaling pathways induced by antigen binding and thereby the cell-specific effector functions triggered. The main part of this review summarizes our understanding of common signaling domains employed in CARs, their interactions among another, and their effects on different cell types. It will, moreover, highlight several less common extracellular and intracellular domains that might permit unique new opportunities. Different antibody-based extracellular antigen-binding domains have been pursued and optimized to strike a balance between specificity, affinity, and toxicity, but these have been reviewed elsewhere. The second cluster of topics is about the cellular vessels expressing the CAR. It is essential to understand the specific attributes of each cell type influencing anti-tumor efficacy, persistence, and safety, and how CAR cells crosstalk with each other and bystander cells. The first part of this review focuses on the progress achieved in adopting different leukocytes for CAR therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.